Parkinson's Disease Evaluated by PET and the Effect of Memantine

This study has been completed.
Lundbeck Foundation
Information provided by:
University of Aarhus Identifier:
First received: September 12, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted

Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).

Background: Disturbances in brain metabolism is thought to contribute to degeneration of neurons in brain of PD patients. Production of toxic oxygen radicals and presence of too much excitatory neurotransmitter (glutamate) due to over activity is involved. These factors can theoretically be alleviated by memantine.

Hypothesis: Memantine decreases metabolism in areas in PD brain known to be over-active. Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET.

Condition Intervention
Parkinson's Disease
Drug: memantine (drug)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Estimated Enrollment: 12
Study Start Date: April 2005
Estimated Study Completion Date: September 2006

Ages Eligible for Study:   50 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Parkinson's Disease (British Brain Bank Criteria)
  • Age 50-70y

Exclusion Criteria:

  • Tobacco use
  • Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)
  • Metal implants contraindicating MR scan
  • Drug use affecting the central nervous system
  • Psychiatric disorders
  • Head trauma or any disorders of the head, skull or brain
  • Drug addiction or use of any kind of illegal substance affecting the central nervous system
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00375778

PET center, Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Lundbeck Foundation
Principal Investigator: Karen Ostergaard, MD, Ph.D Department of Neurology , Aarhus University Hospital, Denmark
  More Information Identifier: NCT00375778     History of Changes
Other Study ID Numbers: 2004-004139-74 
Study First Received: September 12, 2006
Last Updated: September 12, 2006
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by University of Aarhus:
Parkinson's Disease
Positron Emission Tomography
NMDA antagonists
Cerebral Blood Flow
Cerebral Metabolic Rate of Oxygen

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Anti-Dyskinesia Agents
Antiparkinson Agents
Dopamine Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on May 24, 2016